Latest News & Features
.jpg/r%5Bwidth%5D=1280&r%5Bheight%5D=720/9666db60-0c8d-11ef-bb39-41d3e008b149-Gutman-Siegmund_Professional_Cropped%20(2).webp)
Careers
Star litigator moves firms with nearly a dozen attorneys | Biologic drug patent and Hatch-Waxman patent expert David Hanna also joins. 7 May 2024
Big Pharma
Asthma is one of the most common respiratory diseases in the US and the most common chronic disease among children | Israeli pharma giant’s suit comes amid allegations that it keeps life-saving prescriptions treatments artificially high. 7 May 2024
Americas
Two-day event in Boston brings together leading in-house patent counsel | Regeneron, USPTO, the Broad Institute and Novartis among attendees I Agenda includes the UPC, patent strategies, and multijurisdictional patent litigation | Registrations for LSPN Fall now open. 7 May 2024
Big Pharma
AstraZeneca, GSK and Teva among manufacturers accused of “improper” submission of patents | More than 300 patents targeted in second wave of challenges by Federal Trade Commission | ‘Junk patents’ block competition and ramp up prices unfairly, says FTC chair. 2 May 2024
Biotechnology
Ahead of her panel discussion at LSPN North America, BioNTech’s patent counsel, shares insights into her role and ensuring innovations meet the criteria of novelty and nonobviousness. 2 May 2024
Careers
Former senior legal advisor at USPTO brings wealth of life sciences experience | Move represents transition back into private practice after two decades. 2 May 2024
Biotechnology
Settlement comes after Acuitas alleged CureVac deliberately omitted its scientists as inventors on four US patents related to COVID-19 vaccines, claiming co-inventorship | Patents in suit relate to ongoing litigation with Pfizer and BioNTech. 30 April 2024
Biotechnology
Agreement clears the way for Sandoz to launch denosumab biosimilars in May 2025 | Dispute over multiple patents covering Prolia and Xgeva resolved. 30 April 2024
Americas
New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth “billions of dollars”, is filed as UK trial kicks off between Moderna, Pfizer and BioNTech. 26 April 2024
Big Pharma
GSK subsidiary and Exavir Therapeutics end dispute over licensing rights for HIV-drug compounds | Resolution follows allegations that Exavir's actions disrupted ViiV Healthcare's research collaboration with a US university. 25 April 2024